Return to homepagePandemic Pact

Can cardio-renal benefits of new glucose lowering agents mitigate the excess risk associated with COVID-19 infection in type 2 diabetes, a nationwide registry-based evaluation

Grant search

Key facts

  • Disease

    COVID-19

  • start year

    2020

  • Funder

    Novo Nordisk Foundation

  • Principal Investigator

    N/A

  • Research Location

    N/A

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Supportive care, processes of care and management

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Individuals with multimorbidityOther

  • Occupations of Interest

    Unspecified

Abstract

N/A